Targeting leukostasis for the treatment of early diabetic retinopathy

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 9, Issue 3, 2009, Pages 222-229

  Patel, Nishal ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Blood retinal barrier; Diabetic retinopathy; Intracellular adhesion molecule; Leukocyte endothelial interaction; Leukostasis; Vascular endothelial growth factor; Vascular permeability

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN; BEVACIZUMAB; CD18 ANTIGEN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MELOXICAM; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NIPRADILOL; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; RENIN; ROSIGLITAZONE; RUBOXISTAURIN; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADD ON THERAPY; ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CELL ADHESION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; LASER COAGULATION; LEUKOSTASIS; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA BLOOD VESSEL; RETINA ISCHEMIA; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD-RETINAL BARRIER; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; LEUKOSTASIS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73249115843     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152909789007052     Document Type: Review

References (78)

1. The Diabetes Control and Complications Trial Research Group: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N. Engl. J. Med., 1993, 329, 977-986.
2. Scanlon, P.H. The English national screening programme for sight-threatening diabetic retinopathy. J. Med. Screen, 2008, 15, 1-4.
3. Bunce, C.; Wormald, R. Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health, 2006, 6, 58.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352, 837-53.
5. Matthews, D.R.; Stratton, I.M.; Aldington, S.J.; Holman, R.R.; Kohner, E.M. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch. Ophthalmol., 2004, 122, 1631-40.
6. Adler, A.I.; Stevens, R.J.; Neil, A.; Stratton, I.M.; Boulton, A.J.; Holman, R.R. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care, 2002, 25, 894-9.
7. Xu, H.; Chen, M. Forrester, J.V. Para-inflammation in the ageing retina. Prog. Retin. Eye Res., 2009, [Epub a head of print].
8. Singh, R.; Barden, A.; Mori, T.; Beilin, L. Advanced glycation end-products: a review. Diabetologia, 2001, 44,129-46.
9. Scott, J.A.; King, G.L. Oxidative stress and antioxidant treatment in diabetes. Ann. N.Y. Acad. Sci., 2004, 1031, 204-13.
10. Way, K.J.; Katai, N.; G.L.; King. Protein kinase C and the development of diabetic vascular complications. Diabetes Med., 2001, 18, 945-59.
11. Idris, I.; Donnelly, R. Protein kinase C beta inhibition: A novel therapeutic strategy for diabetic microangiopathy. Diabetes Vasc. Dis. Res., 2006, 3,172-8.
12. Booth, G.; Stalker, T.J.; Lefer, A.M.; Scalia, R. Mechanisms of amelioration of glucose-induced endothelial dysfunction following inhibition of protein kinase C in vivo. Diabetes, 2002, 51, 1556-64.
13. Inoguchi, T.; Xia, P.; Kunisaki, M.; Higashi, S.; Feener, E.P.; King, G.L. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am. J. Physiol., 1994, 267, E369-79.
14. Ozaki, H.; Seo, M.S.; Ozaki, K.; Yamada, H.; Yamada, E.; Okamoto, N.; Hofmann, F.; Wood, J.M.; Campochiaro, P.A. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol., 2000, 156, 697-707.
15. Skondra, D.; Noda, K.; Almulki, L.; Tayyari, F.; Frimmel, S.; Nakazawa, T.; Kim, I.K.; Zandi, S.; Thomas, K.L.; Miller, J.W.; Gragoudas, E.S.; Hafezi-Moghadam, A. Characterization of azurocidin as a permeability factor in the retina: involvement in VEGFinduced and early diabetic blood-retinal barrier breakdown. Invest. Ophthalmol. Vis. Sci., 2008, 49, 726-31.
16. Aiello, L.P.; Bursell, S.E.; Clermont, A.; Duh, E.; Ishii, H.; Takagi, C.; Mori, F.; Ciulla, T.A.; Ways, K.; Jirousek, M.; Smith, L.E.; King, G.L. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes, 1997, 46, 1473-80.
17. Suzuma, K.; Takahara, N.; Suzuma, I.; Isshiki, K.; Ueki, K.; Leitges, M.; Aiello, L.P.; King, G.L. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc. Natl. Acad. Sci. USA, 2002, 99, 721-6.
18. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes, 2005, 54, 2188-97.
19. Donnelly, R.; Idris, I.; Forrester, J.V. Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research. Br. J. Ophthalmol., 2004, 88, 145-51.
20. Wautier, J.L.; Setiadi, H.; Vilette, D.; Weill, D.; Wautier, M.P. Leukocyte adhesion to endothelial cells. Biorheology, 1990, 27, 425-32.
21. Anderson, D.C.; Springer, T.A. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. Annu. Rev. Med., 1987, 38, 175-94.
22. Barouch, F.C.; Miyamoto, K.; Allport, J.R.; Fujita, K.; Bursell, S.E.; Aiello, L.P.; Luscinskas, F.W.; Adamis, A.P. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest. Ophthalmol. Vis. Sci., 2000, 41, 1153-8.
23. Dana, N.; Fathallah, D.M.; Arnaout, M.A. Expression of a soluble and functional form of the human beta 2 integrin CD11b/CD18. Proc. Natl. Acad. Sci. USA, 1991, 88, 3106-10.
24. Joussen, A.M.; Poulaki, V.; Le, M.L.; Koizumi, K.; Esser, C.; Janicki, H.; Schraermeyer, U.; Kociok, N.; Fauser, S.; Kirchhof, B.; Kern, T.S.; Adamis, A.P. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J., 2004, 18, 1450-2.
25. Iliaki, E.; Poulaki, V.; Mitsiades, N.; Mitsiades, C.S.; Miller, J.W.; Gragoudas, E.S. Role of {alpha}4 integrin (CD49D) in the pathogenesis of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2009, [Epub a heap of print].
26. Robbins, S.G.; Brem, R.B.; Wilson, D.J.; O'Rourke, L.M.; Robertson, J.E.; Westra, I.; Planck, S.R.; Rosenbaum, J.T. Immunolocalization of integrins in proliferative retinal membranes. Invest. Ophthalmol. Vis. Sci., 1994, 35, 3475-85.
27. Springer, T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell, 1994, 76, 301-14.
28. Song, H.; Wang, L.; Hui, Y. Expression of CD18 on the neutrophils of patients with diabetic retinopathy. Graefes. Arch. Clin. Exp. Ophthalmol., 2007, 245, 24-31.
29. Fusman, R.; Rotstein, R.; Zeltser, D.; Prochorov, V.; Shapira, I.; Bornstein, N.M.; Keren, G.; Roth, A.; Miller, H.I.; Avitzour, D.; Arber, N.; Berliner, S. The state of leukocyte adhesiveness/ aggregation in the peripheral blood of patients with type 2 diabetes and ischemic vascular disease. Acta Diabetol., 2001, 38, 43-9.
30. Joussen, A.M.; Poulaki, V.; Mitsiades, N.; Cai, W-y.; Suzuma, I.; Pak, J.; Ju, S-T.; Rook, S.L.; Esser, P.; Mitsiades, C.; Kirchhof, B.; Adamis, A.P.; Aiello, L.P. Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J., 2003, 17, 76-8.
31. Schroder, S.; Palinski, W.; Schmid-Schonbein, G. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am. J. Pathol., 1991, 139, 81-100.
32. Kelly, L.W.; Barden, C.A.; Tiedeman, J.S.; Hatchell, D.L. Alterations in viscosity and filterability of whole blood and blood cell subpopulations in diabetic cats. Exp. Eye Res., 1993, 56, 341-7.
33. Rao, K.M.; Hatchell, D.L.; Cohen, H.J.; De La Paz, M.A. Alterations in stimulus-induced integrin expression in peripheral blood neutrophils of patients with diabetic retinopathy. Am. J. Med. Sci., 1997, 313, 131-7.
34. Farah, R.; Shurtz-Swirski, R.; Lapin, O. Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment. Cardiovasc. Diabetol., 2008, 7, 20.
35. Goldberg, R.B. Cytokine and Cytokine-like Inflammation Markers, Endothelial Dysfunction and Imbalanced Coagulation in Development of Diabetes and Its Complications. J. Clin. Endocrinol. Metab., 2009.
36. Gustavsson, C.; Agardh, E.; Bengtsson, B.; Agardh, C.D. TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J. Diabetes Complications, 2008, 22, 309-16.
37. Behl, Y.; Krothapalli, P.; Desta, T.; DiPiazza, A.; Roy, S.; Graves, D.T. Diabetes-enhanced tumor necrosis factor-{alpha} production Promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am. J. Pathol., 2008, 172, 1411-1418.
38. Zorena, K.; Mysliwska, J.; Mysliwiec, M.; Balcerska, A.; Lipowski, P.; Raczynska, K. Interleukin-12 and tumour necrosis factor-alpha equilibrium is a prerequisite for clinical course free from late complications in children with type 1 diabetes mellitus. Scand. J. Immunol., 2008, 67, 204-8.
39. Joussen, A.M.; Poulaki, V.; Mitsiades, N.; Kirchhof, B.; Koizumi, K.; Dohmen, S.; Adamis, A.P. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J., 2002, 16, 438-40.
40. Liu, W.; Xu, G.Z.; Jiang, C.H.; Da, C.D. Expression of macrophage colony-stimulating factor (M-CSF) and its receptor in streptozotocin-induced diabetic rats. Curr. Eye Res., 2009, 34, 123-33.
41. Vincent, J.A.; Mohr, S. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes, 2007, 56, 224-30.
42. Ejaz, S.; Chekarova, I.; Ejaz, A.; Sohail, A.; Lim, C.W. Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes. Metab., 2008, 10, 53-63.
43. Naldini, A.; Pucci, A.; Bernini, C.; Carraro, F. Regulation of angiogenesis by Th1- and Th2-type cytokines. Curr. Pharm. Des., 2003, 9, 511-9.
44. Itoi, K.; Nakamura, K.; Oku, H.; Ishizaki, E.; Sugiyama, T.; Ueki, M.; Maeno, T.; Sato, B.; Ikeda, T. Relationship between diabetic macular edema and peripheral Th1/Th2 balance. Ophthalmologica, 2008, 222, 249-53.
45. Gerhardinger, C.; Brown, L.F.; Roy, S.; Mizutani, M.; Zucker, C.L.; Lorenzi, M. Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am. J. Pathol., 1998, 152, 1453-62.
46. Garcia-Ramirez, M.; Canals, F.; Hernandez, C.; Colome, N.; Ferrer, C.; Carrasco, E.; Garcia-Arumi, J.; Simo, R. Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia, 2007, 50, 1294-303.
47. Hernandez, C.; Fonollosa, A.; Garcia-Ramirez, M.; Higuera, M.; Catalan, R.; Miralles, A.; Garcia-Arumi, J.; Simo, R. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care, 2006, 29, 2028-33.
48. Spoerri, P.E.; Ellis, E.A.; Tarnuzzer, R.W.; Grant, M.B. Insulin-like growth factor: receptor and binding proteins in human retinal endothelial cell cultures of diabetic and non-diabetic origin. Growth Horm. IGF Res., 1998, 8, 125-32.
49. Zheng, L.; Szabo, C.; Kern, T.S. Poly(ADP-Ribose) Polymerase Is Involved in the Development of Diabetic Retinopathy via Regulation of Nuclear Factor-{kappa}B. Diabetes, 2004, 53, 2960-2967.
50. Chavakis, T.; Bierhaus, A.; Nawroth, P.P. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect., 2004, 6, 1219-25.
51. Zheng, L.; Szabo, C.; Kern, T.S. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes, 2004, 53, 2960-7.
52. Morigi, M.; Angioletti, S.; Imberti, B.; Donadelli, R.; Micheletti, G.; Figliuzzi, M.; Remuzzi, A.; Zoja, C.; Remuzzi, G. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J. Clin. Invest., 1998, 101, 1905-15.
53. Muranaka, K.; Yanagi, Y.; Tamaki, Y.; Usui, T.; Kubota, N.; Iriyama, A.; Terauchi, Y.; Kadowaki, T.; Araie, M. Effects of peroxisome proliferator- activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model. Invest. Ophthalmol. Vis. Sci., 2006, 47, 4547-52.
54. Sugawara, R.; Hikichi, T.; Kitaya, N.; Mori, F.; Nagaoka, T.; Yoshida, A.; Szabo, C. Peroxynitrite decomposition catalyst, FP15, and poly(ADP-ribose) polymerase inhibitor, PJ34, inhibit leukocyte entrapment in the retinal microcirculation of diabetic rats. Curr. Eye Res., 2004, 29, 11-6.
55. Zheng, L.; Szabó, C.; Kern, T.S. Poly(ADP-Ribose) Polymerase Is Involved in the Development of Diabetic Retinopathy via Regulation of Nuclear Factor. Diabetes, 2004, 53, 2960-2967.
56. Imamoto, E.; Yoshida, N.; Uchiyama, K.; Kuroda, M.; Kokura, S.; Ichikawa, H.; Naito, Y.; Tanigawa, T.; Yoshikawa, T. Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells. Biofactors, 2004, 20, 37-47.
57. Shen, L.Q.; Child, A.; Weber, G.M.; Folkman, J.; Aiello, L.P.; Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch. Ophthalmol., 2008, 126, 793-9.
58. Chen, P.; Scicli, G.M.; Guo, M.; Fenstermacher, J.D.; Dahl, D.; Edwards, A.; Scicli, A.G.; Role of angiotensin II in retinal leukostasis in the diabetic rat. Exp. Eye. Res., 2006, 83, 1041-51.
59. Zhang, J.Z.; Xi, X.; Gao, L.; Kern, S.; Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy. Curr. Eye Res., 2007, 32, 883-9.
60. Nagai, N.; Izumi-Nagai, K.; Oike, Y.; Koto, T.; Satofuka, S.; Ozawa, Y.; Yamashiro, K.; Inoue, M.; Tsubota, K.; Umezawa, K.; et al: Suppression of Diabetes-Induced Retinal Inflammation by Blocking the Angiotensin II Type 1 Receptor or Its Downstream Nuclear Factor-{kappa}B Pathway. Invest. Ophthalmol. Vis. Sci., 2007, 48, 4342-4350.
61. Clermont, A.; Bursell, S.E.; Feener, E.P: Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J. Hypertens. Suppl., 2006, 24, S73-80.
62. Chen, P.; Guo, A.M.; Edwards, P.A.; Trick, G.; Scicli, A.G.: Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 293, R1619-29.
63. Leal, E.C.; Manivannan, A.; Hosoya, K.; Terasaki, T.; Cunha-Vaz, J.; Ambrosio, A.F.; Forrester, J.V.: Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci., 2007, 48, 5257-65.
64. Ono, R.; Kakehashi, A.; Ito, Y.; Sugi, N.; Makino, S.; Kobayashi, E.; Hakamada, Y.; Takagi, Y.; Kitazume, Y.; Kawakami, M. Effect of topical nipradilol on retinal microvascular leukocyte adhesion in diabetic rats. Ophthalmic. Res., 2006, 38, 270-3.
65. S Miyahara, J Kiryu, K Yamashiro, K Miyamoto, F Hirose, H Tamura, H Katsuta, K Nishijima, A Tsujikawa, Y Honda: Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. Am. J. Pathol., 2004, 164, 1697-706.
66. Nakazawa, T.; Takahashi, H.; Nishijima, K.; Shimura, M.; Fuse, N.; Tamai, M.; Hafezi-Moghadam, A.; Nishida, K. Pitavastatin prevents NMDA-induced retinal ganglion cell death by suppressing leukocyte recruitment. J. Neurochem., 2007, 100, 1018-31.
67. Moore, T.C.B.; Moore, J.E.; Kaji, Y.; Frizzell, N.; Usui, T.; Poulaki, V.; Campbell, I.L.; Stitt, A.W.; Gardiner, T.A.; Archer, D.B.; Adamis, A.P. The Role of Advanced Glycation End Products in Retinal Microvascular Leukostasis. Invest. Ophthalmol. Vis. Sci., 2003, 44, 4457-4464.
68. Kaji, Y.; Usui, T.; Ishida, S.; Yamashiro, K.; Moore, T.C.; Moore, J.; Yamamoto, Y.; Yamamoto, H.; Adamis, A.P. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol. Vis. Sci., 2007, 48, 858-65.
69. Tang, S.; Scheiffarth, O.F.; Thurau, S.R.; Wildner, G. Cells of the immune system and their cytokines in epiretinal membranes and in the vitreous of patients with proliferative diabetic retinopathy. Ophthalmic. Res., 1993, 25, 177-85.
70. Miyamoto, K.; Khosrof, S.; Bursell, S.E.; Moromizato, Y.; Aiello, L.P.; Ogura, Y.; Adamis, A.P. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am. J. Pathol., 2000, 156, 1733-9.
71. McLeod, D.; Lefer, D.; Merges, C.; Lutty, G. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am. J. Pathol., 1995, 147, 642-653.
72. Kern, T.S.; Miller, C.M.; Du, Y.; Zheng, L.; Mohr, S.; Ball, S.L.; Kim, M.; Jamison, J.A.; Bingaman, D.P. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes, 2007, 56,373-9.
73. Funatsu, H.; Yamashita, H.; Ikeda, T.; Mimura, T.; Eguchi, S.; Hori, S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology, 2003, 110, 1690-6.
74. Tamura, H.; Miyamoto, K.; Kiryu, J.; Miyahara, S.; Katsuta, H.; Hirose, F.; Musashi, K.; Yoshimura, N. Intravitreal Injection of Corticosteroid Attenuates Leukostasis and Vascular Leakage in Experimental Diabetic Retina. Invest. Ophthalmol. Vis. Sci., 2005, 46, 1440-1444.
75. Harhaj, N.S.; Felinski, E.A.; Wolpert, E.B.; Sundstrom, J.M.; Gardner, T.W.; Antonetti, D.A. VEGF Activation of Protein Kinase C Stimulates Occludin Phosphorylation and Contributes to Endothelial Permeability. Invest. Ophthalmol. Vis. Sci., 2006, 47, 5106-5115.
76. Xu, X.; Zhu, Q.; Xia, X.; Zhang, S.; Gu, Q.; Luo, D. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr. Eye Res., 2004, 28, 251-6.
77. Malchiodi-Albedi, F.; Matteucci, A.; Bernardo, A.; Minghetti, L. PPAR-gamma, microglial cells, and ocular inflammation: new venues for potential therapeutic approaches. PPAR Res., 2008, 2008, 295784.
78. Joussen, A.M.; Poulaki, V.; Mitsiades, N.; Kirchhof, B.; Koizumi, K.; Dohmen, S.; Adamis, A.P. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-a suppression. FASEB J., 2002, 16(3), 438-440.